



# Resource impact statement

Resource impact

Published: 17 November 2021

[www.nice.org.uk](http://www.nice.org.uk)

## No significant resource impact is anticipated

NICE has recommended nivolumab for adjuvant treatment of completely resected oesophageal or gastro-oesophageal junction cancer in adults who have residual disease after previous neoadjuvant chemoradiotherapy. It is recommended only if the company provides nivolumab according to the commercial arrangement.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the population size is small. Less than 200 adults per year who have residual disease after previous neoadjuvant chemoradiotherapy are expected to be eligible for treatment with nivolumab for adjuvant treatment of completely resected oesophageal or gastro-oesophageal junction cancer.

Nivolumab has a discount that is commercial in confidence. For enquiries about the patient access scheme contact the manufacturer.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.